Search MBRX
Moleculin Biotech, Inc.
Nasdaq · CIK 1659617
Last close0.49
Daily change-0.02 (-3.37%)
10 Years gain-100.00%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
MBRX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
21.5Momentum
n/aAcceleration
0.0Confidence
64.0Annual Revenue10
Quarterly Revenue33
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality12.5 / 25
Capital Efficiency2.0 / 20
Balance Sheet5.9 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
ROIC declining · MEDIUMROIC declined by 67.6974 percentage points.
Key Metrics
Revenue Growth TTMn/aINSUFFICIENT_HISTORY
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Marginn/aMISSING
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-236.01%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $0.00 | $0.00 | -$25.10M | -$22.74M | -$22.74M | n/a | n/a | n/a | -303.74% | n/a |
| 2025 FY Dec 31, 2024 | $0.00 | $0.00 | -$26.64M | -$23.86M | -$23.88M | n/a | n/a | n/a | -294.19% | n/a |
| 2024 FY Dec 31, 2023 | $0.00 | $0.00 | -$29.63M | -$23.59M | -$23.72M | n/a | n/a | n/a | -285.05% | n/a |
| 2023 FY Dec 31, 2022 | $0.00 | $0.00 | -$30.64M | -$27.64M | -$27.71M | n/a | n/a | n/a | -282.51% | n/a |
| 2022 FY Dec 31, 2021 | $0.00 | $0.00 | -$22.97M | -$18.95M | -$18.97M | n/a | n/a | n/a | -339.88% | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $0.00 | sum latest 4 fiscal quarters Revenue | OK | 0001437749-26-027688, 0001437749-25-034839 |
| Revenue Growth TTM | n/a | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | INSUFFICIENT_HISTORY | 0001437749-26-027688, 0001437749-25-034839 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001437749-26-008841 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001437749-26-008841 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001437749-26-008841 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001437749-26-027688, 0001437749-25-034839 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| ROIC | -236.01% | NOPAT / Average Invested Capital | OK | 0001437749-26-027688, 0001437749-25-034839 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001437749-26-027688 |
| Current Ratio | 0.94x | Current Assets / Current Liabilities | OK | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001437749-26-008841 |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | derived |
| Gross Margin Delta 1Y | n/a | GrossMargin_current - GrossMargin_prior_year | INSUFFICIENT_HISTORY | derived |